Cardiovascular biomarker phenotype associated with immune checkpoint inhibitor therapy in patients with non-small cell lung cancer: an exploratory blood transcriptome study
Background Immune checkpoint inhibitors (ICIs) have transformed the management of advanced non-small cell lung cancer (NSCLC), but their use is associated with potentially serious immune-related cardiotoxicity, often reflected by elevations in N-terminal pro-B-type natriuretic peptide (NT-proBNP). Identifying patients...